跳至主要内容
临床试验/NL-OMON41162
NL-OMON41162已完成3 期

The EPPI Trial - Enoxaparin for the Prevention of Preeclampsia and Intrauterine growth restriction - a open-label randomised controlled trial - The EPPI Trial

Academisch Medisch Centrum0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Previous preeclampsia delivered < 36 weeks (ie. up to 35+6 weeks - spontaneous or iatrogenic) in last ongoing pregnancy reaching >12 weeks.
  • 2. Previous SGA <10th C delivered < 36 weeks (ie. up to 35+6 weeks - spontaneous or iatrogenic) in last ongoing pregnancy reaching >12 weeks.
  • 3. Previous SGA <3rd C delivered at any gestation in last ongoing pregnancy reaching >12 weeks.

排除标准

  • 1. Any contraindication to LMWH
  • 2. Requirement for LMWH eg. previous thrombosis, APS (referring clinician decision)
  • 3. Previous successful pregnancy with LMWH treatment
  • 4. Multiple pregnancy
  • 5. Known pre-existing type 1/2 diabetes or renal disease (with serum creatinine >150)
  • 6. Thrombocytopenia (platelet count <80) prior to randomisation
  • 7. Known major fetal anomaly/chromosomal abnormality
  • 8. Known cause of prior FGR other than reduced uteroplacental blood flow eg. maternal infections associated with FGR, use of cigarettes, alcohol, illicit drugs or other toxic exposures such as medication associated with FGR (referring clinician decision).

研究者

相似试验